Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
Novartis gets FDA nod for advanced breast-cancer treatment
Novartis gets FDA nod for advanced breast-cancer treatment
Marketwatch
Novartis
FDA
advanced breast cancer
Piqray
Flag link:
Novartis on goal to hit mid-30s margins by 2022
Novartis on goal to hit mid-30s margins by 2022
BioCentury
Novartis
M&A
Flag link:
Novartis gene therapy approved, but will come at cost of more than $2 million
Novartis gene therapy approved, but will come at cost of more than $2 million
Biopharma Dive
SMA
Novartis
drug pricing
Zolgensma
Flag link:
Novartis’ inhaled asthma combo QVM149 succeeds in two phase 2 trials
Novartis’ inhaled asthma combo QVM149 succeeds in two phase 2 trials
Pharmaceutical Business Review
Novartis
QVM149
clinical trials
asthma
Flag link:
Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Endpoints
Novartis
R&D
Sandoz
Pharma CEOs
Vas Narasimhan
Flag link:
Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range
Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range
Yahoo/Reuters
Novartis
Pharma CEOs
Vas Narasimhan
gene therapy
SMA
drug pricing
Zolgensma
Flag link:
Novartis' asthma triplet beats GSK's Advair in phase 2 trial
Novartis' asthma triplet beats GSK's Advair in phase 2 trial
Fierce Pharma
Novartis
asthma
QVM149
GSK
Advair
clinical trials
Flag link:
Verily lures major pharmas with promise of speedier clinical research
Verily lures major pharmas with promise of speedier clinical research
BioPharma Dive
Verily
Alphabet
clinical trials
Pfizer
Novartis
Sanofi
Otsuka
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Incyte
Novartis
Athersys
ResTORbio
Bellerophon Therapeutics
Eli Lilly
CymaBay
Bicycle Therapeutics
Peloton Therapeutics
Ideaya
IPOs
Flag link:
GSK and Novartis liniment marketing misled Australian consumers: court
GSK and Novartis liniment marketing misled Australian consumers: court
Reuters
GSK
Novartis
Australia
Flag link:
Upcoming events – Phase III data for Chiasma and Novartis
Upcoming events – Phase III data for Chiasma and Novartis
EP Vantage
Chiasma
acromegaly
Mycapssa
clinical trials
multiple sclerosis
Novartis
ofatumumab
Flag link:
Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model
Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model
CNBC
gene therapy
cancer
Novartis
Pharma CEOs
Vas Narasimhan
Flag link:
Alcon Beats Expectations Since its Split from Novartis
Alcon Beats Expectations Since its Split from Novartis
Medical Devices and Diagnostics Industry
Alcon
earnings
Novartis
eye health
Flag link:
Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead
Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead
Endpoints
CAR-T
MorphoSys
Novartis
Gilead Sciences
tafasitamab
DLBCL
Flag link:
Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K
Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K
Endpoints
Novartis
Kymriah
Japan
CAR-T
Flag link:
Novartis' Sandoz does digital from back office to 'not just apps' therapeutics
Novartis' Sandoz does digital from back office to 'not just apps' therapeutics
Fierce Pharma
digital pharma
Sandoz
Novartis
Flag link:
Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS
Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS
Pharmaceutical Business Review
Novartis
Gilenya
Relapsing Remitting Multiple Sclerosis
Flag link:
Novartis vows to fight U.S. price-fixing claims against Sandoz unit
Novartis vows to fight U.S. price-fixing claims against Sandoz unit
Yahoo/Reuters
Novartis
Sandoz
generics
price fixing
Flag link:
Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal
Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal
Fierce Pharma
Takeda
Shire
Novartis
M&A
Xiidra
dry eye disease
Flag link:
Novartis sees Saudi Arabia as promising market for producing its cancer drugs
Novartis sees Saudi Arabia as promising market for producing its cancer drugs
Fierce Pharma
Novartis
oncology
cancer
Saudi Arabia
Flag link:
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »